Please login to the form below

Not currently logged in
Email:
Password:

Parkinson's

This page shows the latest Parkinson's news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

There will be no change to Lilly’s commercial infrastructure in Basingstoke, it says. ... a small-molecule dopamine D1 modulator for dementia caused by Parkinson’s disease.

Latest news

  • Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

    $1b purchase of  Prexton Therapeutics and phase 2 Parkinson’s disease therapy foliglurax. ... Deborah Dunsire, CEO, Lundbeck. Dunsire said Alder is “an excellent strategic fit for Lundbeck’s focused expertise in brain diseases and organisational

  • Bayer takes control of BlueRock stem cell joint venture Bayer takes control of BlueRock stem cell joint venture

    The decision gives Bayer complete control of BlueRock’s cell therapy pipeline headed by a candidate for Parkinson’s disease that is due to start clinical trials this year and spanning ... The deal values BlueRock at around $1bn. The lead programme in

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    periods in Parkinson’s disease, as well as Theratechnologies’ Trogarzo (ibalizumab) as an add-on treatment for drug resistant HIV. ... Squibb got the go-ahead for Empliciti (elotuzumab) alongside Celgene’s Pomalyst (pomalidomide) and dexamethasone

  • Acadia’s drive to extend use of Nuplazid hits a wall Acadia’s drive to extend use of Nuplazid hits a wall

    Shares in company down. Acadia Pharmaceutical’s Nuplazid was the first-ever drug to be approved to treat psychosis associated with Parkinson’s disease, but the company’s hopes of extending ... Nuplazid (pimavanserin) is Acadia’s only approved

  • Intec sounds a sad note as Accordion Parkinson’s trial fails Intec sounds a sad note as Accordion Parkinsons trial fails

    Intec’s lifeline now is Novartis partnership. Shares in Intec Pharma have been poleaxed after a phase 3 trial of a Parkinson’s disease drug based on its Accordion delivery technology ... to the patient, performed no better than the standard

More from news
Approximately 37 fully matching, plus 222 partially matching documents found.

Latest Intelligence

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as Parkinson’s and Huntington’s disease. ... Examples of ongoing projects include two which target the immune system with an aim to halt nerve cell damage in

  • Genomics integration: can the NHS rise to the challenge? Genomics integration: can the NHS rise to the challenge?

    But it’s about pitching.”. Helen Parkinson (pictured below), head of molecular archival resources at the European Bioinformatics Institute, was also on the panel. ... Genomics has to be collaborative, and that’s what I love about it.

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinsons disease trials

    ‘Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development’. ... Taking all these lessons learned into consideration should markedly lower the risk of a false negative result in clinical trials for disease-modifying

  • Tackling a formidable foe Tackling a formidable foe

    MAVENCLAD’S short-course oral therapy profile is a bonus to a condition freighted with psychological drag-weights. ... But the battle to beat MS continues at pace with the tantalising prospect that wins in the lab could also be translated to treatments

  • Six degrees of participation Six degrees of participation

    For example, a Parkinson’s patient recently told me that although he understood the importance of ‘participating’, he didn’t want to spend any more time than necessary thinking about ... That’s powerful evidence. And it’s right at our

More from intelligence
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    He said: “I am thrilled to join Voyager at this important time during the company’s evolution. ... Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis. ... future. “At the same time we welcome Dennis as a new member of

  • Voyager Therapeutics appoints chief financial officer Voyager Therapeutics appoints chief financial officer

    This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a ... I am thrilled to join the Voyager team and meaningfully contribute

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... Dr Mikael Dolsten, president of

More from appointments
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics